Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

  • Lahiguera, Álvaro
  • Hyroššová, Petra
  • Figueras, Agnès
  • Garzón, Diana
  • Moreno, Roger
  • Soto-Cerrato, Vanessa
  • Serra Elizalde, Violeta
Inhibidors de la PARP; Metabolisme del càncer; Metformina, Inhibidores de PARP, Metabolismo del cáncer; Metformina, PARP inhibitors; Cancer metabolism; Metformin, Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective (HRD) cancers rely on oxidative metabolism to supply NAD+ and ATP for poly(ADP-ribose) polymerase (PARP)-dependent DNA repair mechanisms. Studies in breast and ovarian cancer HRD models depict a metabolic shift that includes enhanced expression of the oxidative phosphorylation (OXPHOS) pathway and its key components and a decline in the glycolytic Warburg phenotype. Hence, HRD cells are more sensitive to metformin and NAD+ concentration changes. On the other hand, shifting from an OXPHOS to a highly glycolytic metabolism interferes with the sensitivity to PARP inhibitors (PARPi) in these HRD cells. This feature is associated with a weak response to PARP inhibition in patient-derived xenografts, emerging as a new mechanism to determine PARPi sensitivity. This study shows a mechanistic link between two major cancer hallmarks, which in turn suggests novel possibilities for specifically treating HRD cancers with OXPHOS inhibitors., This study has been funded by the Ministerio de Ciencia, Innovación y Universidades, which is part of the Agencia Estatal de Investigación (AEI), through the project SAF2017-85869-R (cofunded by the European Regional Development Fund (ERDF), a way to build Europe) to FV and BFU2015-66030-R to JCP; by the FIS PI15/00854 and FIS PI16/01898 (Instituto Carlos III, cofunded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe) to MAP and AVillanueva and with the support of the Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia (2017SGR449) to FV. We thank the CERCA Program/Generalitat de Catalunya for their institutional support. We particularly wish to acknowledge the collaboration of the patients and the IDIBGI Biobank (Biobanc IDIBGI, B.0000872), which is part of the Spanish National Biobank Network and the Xarxa de Bancs de Tumors de Catalunya (XBTC), financed by the Pla Director d'Oncologia de Catalunya, Spain. We thank Cristina Saura (Breast Cancer & Melanoma Group) and people from the Experimental Therapeutics Group at VHIO and Sara González (Unitat de Diagnòstic Molecular, ICO-Duran i Reynals). We thank H. Simon, R. Bartrons, and A. Manzano (Universitat de Barcelona) and A. Vaquero (IDIBELL) for reagents.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immune Cell Associations with Cancer Risk

  • Palomero, Luis|||0000-0002-9144-1017
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • de Cid, Rafael|||0000-0003-3579-6777
  • Espín, Roderic
  • Barnes, Daniel R.|||0000-0002-3781-7570
  • Blommaert, Eline
  • Gil-Gil, Miguel|||0000-0003-1380-2718
  • Falo, Catalina|||0000-0002-5714-6823
  • Stradella, Agostina|||0000-0002-2307-8869
  • Ouchi, Dan|||0000-0002-8630-152X
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • Violán, Concepció|||0000-0003-3309-5360
  • Peña-Chilet, María|||0000-0002-6445-9617
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Extremera, Ana Isabel
  • García-Valero, Mar
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Mateo, Francesca|||0000-0002-2342-7010
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Beesley, Jonathan
  • Chenevix-Trench, Georgia
  • Roux, Cecilia
  • Mak, Tak
  • Brunet, Joan|||0000-0003-1945-3512
  • Hakem, Razq
  • Gorrini, Chiara
  • Antoniou, Antonis C.
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in immune and/or stromal cell contents in the corresponding tissue. Predicted target genes show expression and regulatory associations with immune features. Polygenic risk scores also reveal associations with immune and/or stromal cell contents, and breast cancer scores show consistent results in normal and tumor tissue. SH2B3 links peripheral alterations of several immune cell types to the risk of this malignancy. Pleiotropic SH2B3 variants are associated with breast cancer risk in BRCA1/2 mutation carriers. A retrospective case-cohort study indicates a positive association between blood counts of basophils, leukocytes, and monocytes and age at breast cancer diagnosis. These findings broaden our knowledge of the role of the immune system in cancer and highlight promising prevention strategies for individuals at high risk. Immunology; Cancer Systems Biology; Cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Disease networks identify specific conditions and pleiotropy influencing multimorbidity in the general population

  • Amell, A.
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • Palomero, L.
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • Serra-Musach, J.
  • Comellas, Francesc|||0000-0003-4523-0240
  • de Cid, Rafael|||0000-0003-3579-6777
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Violán, Concepció|||0000-0003-3309-5360
Multimorbidity is an emerging topic in public health policy because of its increasing prevalence and socio-economic impact. However, the age- and gender-dependent trends of disease associations at fine resolution, and the underlying genetic factors, remain incompletely understood. Here, by analyzing disease networks from electronic medical records of primary health care, we identify key conditions and shared genetic factors influencing multimorbidity. Three types of diseases are outlined: "central", which include chronic and non-chronic conditions, have higher cumulative risks of disease associations; "community roots" have lower cumulative risks, but inform on continuing clustered disease associations with age; and "seeds of bursts", which most are chronic, reveal outbreaks of disease associations leading to multimorbidity. The diseases with a major impact on multimorbidity are caused by genes that occupy central positions in the network of human disease genes. Alteration of lipid metabolism connects breast cancer, diabetic neuropathy and nutritional anemia. Evaluation of key disease associations by a genome-wide association study identifies shared genetic factors and further supports causal commonalities between nervous system diseases and nutritional anemias. This study also reveals many shared genetic signals with other diseases. Collectively, our results depict novel population-based multimorbidity patterns, identify key diseases within them, and highlight pleiotropy influencing multimorbidity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • Bustamante-Madrid, Pilar|||0000-0003-4540-9742
  • Camps-Fajol, Cristina
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Shimelis, Hermela
  • Montanuy Escribano, Helena
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Castillo, Pau
  • Soucy, Penny
  • Martrat, Griselda
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Cuadras, Daniel|||0000-0001-8780-1764
  • García, María J.
  • Gayarre, Javier|||0000-0003-0377-6712
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Benitez, Javier|||0000-0002-0923-7202
  • Couch, Fergus J.
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk factors. Here we identify the tumor suppressor CDK5RAP3 as a novel BRCA2 helical domain-interacting protein. CDK5RAP3 depletion induced DNA damage resistance, homologous recombination and single-strand annealing upregulation, and reduced spontaneous and DNA damage-induced genomic instability, suggesting that CDK5RAP3 negatively regulates double-strand break repair in the S-phase. Consistent with this cellular phenotype, analysis of transcriptomic data revealed an association between low CDK5RAP3 tumor expression and poor survival of breast cancer patients. Finally, we identified common genetic variations in the CDK5RAP3 locus as potentially associated with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Our results uncover CDK5RAP3 as a critical player in DNA repair and breast cancer outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biological basis of extensive pleiotropy between blood traits and cancer risk

  • Pardo-Cea, Miguel Ángel|||0000-0003-4823-6613
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Esteve, Anna|||0000-0002-1962-971X
  • Palade, Joanna
  • Espín, Roderic
  • Mateo, Francesca|||0000-0002-2342-7010
  • Alsop, Eric
  • Alorda, Marc
  • Blay, Natalia|||0000-0002-7160-8529
  • Baiges, Alexandra
  • Shabbir, Arzoo
  • Comellas, Francesc|||0000-0003-4523-0240
  • Gómez Moruno, Antonio
  • Arnan, Montserrat
  • Teule, Alex|||0000-0003-0028-7200
  • Salinas, Monica
  • Berrocal, Laura
  • Brunet, Joan|||0000-0003-1945-3512
  • Rofes, Paula|||0000-0001-6045-7879
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Conesa, Miquel
  • Rojas, Juan Jose
  • Velten, Lars
  • Fendler, Wojciech
  • Smyczynska, Urszula
  • Chowdhury, Dipanjan
  • Zeng, Yong
  • He, Housheng Hansen
  • Li, Rong
  • Van Keuren-Jensen, Kendall
  • de Cid, Rafael|||0000-0003-3579-6777
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Background: The immune system has a central role in preventing carcinogenesis. Alteration of systemic immune cell levels may increase cancer risk. However, the extent to which common genetic variation influences blood traits and cancer risk remains largely undetermined. Here, we identify pleiotropic variants and predict their underlying molecular and cellular alterations. Methods: Multivariate Cox regression was used to evaluate associations between blood traits and cancer diagnosis in cases in the UK Biobank. Shared genetic variants were identified from the summary statistics of the genome-wide association studies of 27 blood traits and 27 cancer types and subtypes, applying the conditional/conjunctional false-discovery rate approach. Analysis of genomic positions, expression quantitative trait loci, enhancers, regulatory marks, functionally defined gene sets, and bulk- and single-cell expression profiles predicted the biological impact of pleiotropic variants. Plasma small RNAs were sequenced to assess association with cancer diagnosis. Results: The study identified 4093 common genetic variants, involving 1248 gene loci, that contributed to blood-cancer pleiotropism. Genomic hotspots of pleiotropism include chromosomal regions 5p15-TERT and 6p21-HLA. Genes whose products are involved in regulating telomere length are found to be enriched in pleiotropic variants. Pleiotropic gene candidates are frequently linked to transcriptional programs that regulate hematopoiesis and define progenitor cell states of immune system development. Perturbation of the myeloid lineage is indicated by pleiotropic associations with defined master regulators and cell alterations. Eosinophil count is inversely associated with cancer risk. A high frequency of pleiotropic associations is also centered on the regulation of small noncoding Y-RNAs. Predicted pleiotropic Y-RNAs show specific regulatory marks and are overabundant in the normal tissue and blood of cancer patients. Analysis of plasma small RNAs in women who developed breast cancer indicates there is an overabundance of Y-RNA preceding neoplasm diagnosis. Conclusions: This study reveals extensive pleiotropism between blood traits and cancer risk. Pleiotropism is linked to factors and processes involved in hematopoietic development and immune system function, including components of the major histocompatibility complexes, and regulators of telomere length and myeloid lineage. Deregulation of Y-RNAs is also associated with pleiotropism. Overexpression of these elements might indicate increased cancer risk.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

  • Lahiguera, Álvaro
  • Hyroššová, Petra
  • Figueras, Agnès
  • Garzón, Diana
  • Moreno, Roger
  • Soto-Cerrato, Vanessa
  • Serra Elizalde, Violeta
Inhibidors de la PARP; Metabolisme del càncer; Metformina, Inhibidores de PARP, Metabolismo del cáncer; Metformina, PARP inhibitors; Cancer metabolism; Metformin, Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective (HRD) cancers rely on oxidative metabolism to supply NAD+ and ATP for poly(ADP-ribose) polymerase (PARP)-dependent DNA repair mechanisms. Studies in breast and ovarian cancer HRD models depict a metabolic shift that includes enhanced expression of the oxidative phosphorylation (OXPHOS) pathway and its key components and a decline in the glycolytic Warburg phenotype. Hence, HRD cells are more sensitive to metformin and NAD+ concentration changes. On the other hand, shifting from an OXPHOS to a highly glycolytic metabolism interferes with the sensitivity to PARP inhibitors (PARPi) in these HRD cells. This feature is associated with a weak response to PARP inhibition in patient-derived xenografts, emerging as a new mechanism to determine PARPi sensitivity. This study shows a mechanistic link between two major cancer hallmarks, which in turn suggests novel possibilities for specifically treating HRD cancers with OXPHOS inhibitors., This study has been funded by the Ministerio de Ciencia, Innovación y Universidades, which is part of the Agencia Estatal de Investigación (AEI), through the project SAF2017-85869-R (cofunded by the European Regional Development Fund (ERDF), a way to build Europe) to FV and BFU2015-66030-R to JCP; by the FIS PI15/00854 and FIS PI16/01898 (Instituto Carlos III, cofunded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe) to MAP and AVillanueva and with the support of the Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia (2017SGR449) to FV. We thank the CERCA Program/Generalitat de Catalunya for their institutional support. We particularly wish to acknowledge the collaboration of the patients and the IDIBGI Biobank (Biobanc IDIBGI, B.0000872), which is part of the Spanish National Biobank Network and the Xarxa de Bancs de Tumors de Catalunya (XBTC), financed by the Pla Director d'Oncologia de Catalunya, Spain. We thank Cristina Saura (Breast Cancer & Melanoma Group) and people from the Experimental Therapeutics Group at VHIO and Sara González (Unitat de Diagnòstic Molecular, ICO-Duran i Reynals). We thank H. Simon, R. Bartrons, and A. Manzano (Universitat de Barcelona) and A. Vaquero (IDIBELL) for reagents.